{"id":50314,"date":"2022-10-26T11:30:44","date_gmt":"2022-10-26T06:00:44","guid":{"rendered":"https:\/\/corpbiz.io\/learning\/?p=50314"},"modified":"2022-10-26T11:30:47","modified_gmt":"2022-10-26T06:00:47","slug":"cdsco-issues-a-list-of-drugs-medical-devices-and-cosmetics","status":"publish","type":"post","link":"https:\/\/corpbiz.io\/learning\/cdsco-issues-a-list-of-drugs-medical-devices-and-cosmetics\/","title":{"rendered":"CDSCO Issues a List of Drugs, Medical Devices, and Cosmetics \u2013 An Overview"},"content":{"rendered":"\n

The CDSCO has noted that Spurious or Quality or Adulterated or Misbranded of Drugs products, medical devices and Cosmetic products are formulations manufactured concealing the true identity of the product and made to resemble another such product, especially any popular brand, to deceive the customer and cash in on the popularity of the original. The products may or may not contain active ingredients. Spurious or adulterated drugs and cosmetics products are usually manufactured by unlicensed anti-social elements but sometimes licensed manufacturers may also be involved. Such adulterated products are those products which are found to contain an adulterated or substituted product or contaminated with filth rendering it injurious to health. By taking into consideration, on 17th<\/sup> October, CDSCO (Central Drug Standard Control Organisation<\/strong>[1]<\/strong><\/a><\/sup>) <\/strong>issued a list of Drugs, Medical Devices, and Cosmetics declared as Spurious or Quality or Adulterated or Misbranded for the month of September 2022. In this blog, we will discuss a list of Drugs, Medical Devices, and Cosmetics declared as Spurious or Quality or Adulterated or Misbranded for the month of September 2022, issued by CDSCO.<\/p>\n\n\n\n

Total Number\nof Samples tested by CDSCO – List of Drugs, Medical Devices, and Cosmetics\nissued by CDSCO<\/h2>\n\n\n\n

Below is the table showing a total number of samples tested by CDSCO in the month of September 2022:<\/p>\n\n\n\n
\n Particulars<\/strong>\n <\/td>\n Number\n of Samples<\/strong>\n <\/td><\/tr>
\n Total Number of Samples\n Tested\n <\/td>\n 1456\n <\/td><\/tr>
\n Total No. of Samples declared\n as Not of Standard Quality\n <\/td>\n 59\n <\/td><\/tr>
\n Total No. of Samples declared\n as of Standard Quality\n <\/td>\n 1397\n <\/td><\/tr>
\n Total No. of Samples declared\n as Misbranded\n <\/td>\n _\n <\/td><\/tr>
\n Total No. of Samples declared\n as Spurious\n <\/td>\n _\n <\/td><\/tr><\/tbody><\/table>\n\n\n\n

Detailed List\nof Drugs, Medical Devices, and Cosmetics issued by CDSCO for the Month of\nSeptember 2022<\/h2>\n\n\n\n

Following is the list of Drugs, Medical Devices, and Cosmetics declared as Spurious or not of Standard Quality or Misbranded or Adulterated issued by CDSCO for the Month of September 2022:<\/p>\n\n\n\n
\n Name\n of Medical Devices or Cosmetics or Drugs<\/strong>\n <\/td>\n Reason\n for Failure<\/strong>\n <\/td><\/tr>
\n Pantoprazole Sodium Gastro Resistant\n Tablets I.P. Pantofer-40 Tablets\n <\/td>\n Dissolution (Buffer Stage)\n <\/td><\/tr>
\n Ocean-OZ (Ofloxacin &\n Ornidazole Tablets)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Ornigyl-O (Ofloxacin and\n Ornidazole Tablets I.P.)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Paracetamol Tablets IP\n (Larkin)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n NTP-650 (Paracetamol Tablets\n I.P. 650 mg.)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Paracetamol Tablets IP 650 mg\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Dried Ferrous Sulphate &\n Folic Acid Tablets IP\n <\/td>\n Description\n <\/td><\/tr>
\n Montelukast Sodium &\n Levocetirizine Dihydrochloride Tablets IP (Viznil)\n <\/td>\n Description\n <\/td><\/tr>
\n ALCIFLOX 500 (Ciprofloxacin\n Tablets IP)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Rabeprazole Gastro Resistant\n Tablets I.P. 20 mg\n <\/td>\n Assay\n <\/td><\/tr>
\n Ascorbic Acid Tablets IP 500\n mg\n <\/td>\n Description\n <\/td><\/tr>
\n WARCETIZ (Cetirizine\n Hydrochloride Tablets IP)\n <\/td>\n Description\n <\/td><\/tr>
\n KOOCAL-500 (Calcium with\n Vitamin D Tablets IP)\n <\/td>\n Identification & Assay of\n Vitamin D3\n <\/td><\/tr>
\n Glimepiride Tablets IP 1 mg.\n Glimvale-1 Tablets\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Levocetirizine Dihydrochloride\n Syrup\n <\/td>\n pH\n <\/td><\/tr>
\n OMECAP (Omeprazole Capsules\n IP 20 mg)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Ranitidine Tablets IP 150 mg\n (ACILOC 150)\n <\/td>\n Description\n <\/td><\/tr>
\n IM-OK-(Levocetirizine\n Hydrochloride Tablets IP)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Co-trimoxazole Tablets IP SS\n <\/td>\n Disintegration\n <\/td><\/tr>
\n Rosuvastatin Calcium Tablets\n IP 10 mg\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Sin-DSR (Rabeprazole Sodium\n (EC) & Domperidone Sustained Release Capsules)\n <\/td>\n Assay for Raberprazole Sodium\n <\/td><\/tr>
\n Atorvastatin Tablets IP 20 mg\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Levothyroxine Sodium Tablets\n IP 50 mcg\n <\/td>\n Assay\n <\/td><\/tr>
\n Lvcipro 500 – tablets\n (Ciprofloxacin Hydrochloride Tablets IP)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Zinc Sulphate Dispersible\n Tablets IP 20 mg\n <\/td>\n Uniformity of Dispersion\n & Disintegration\n <\/td><\/tr>
\n MONTERUS-L (Montelukast\n Sodium & Levocetirizine Hydrochloride Tablets I.P.)\n <\/td>\n Dissolution and Description\n <\/td><\/tr>
\n Azithromycin Oral Suspension\n IP 200 mg\/ 5 ml\n <\/td>\n Assay or Content of Anhydrous\n Azithromycin\n <\/td><\/tr>
\n ACILOC 150 (RANITIDINE Tablets\n IP 150 mg)\n <\/td>\n Description\n <\/td><\/tr>
\n Azithromycin Tablets IP 500mg\n AZUSTAN-500 Tablets\n <\/td>\n Dissolution\n <\/td><\/tr>
\n Moxmed-500 (Amoxycillin\n Capsule I.P. 500mg)\n <\/td>\n Dissolution & Array\n <\/td><\/tr>
\n Telmisartan Tablets I.P. 40\n mg\n <\/td>\n Dissolution\n <\/td><\/tr>
\n AMITRYN-C (Chlordiazepoxide &\n Amitriptyline Hydrochloride Tablets U.S.P.)\n <\/td>\n Assay of Chlordiazepoxide\n <\/td><\/tr>
\n Thirobal -5 (Carbimazole\n Tablets I.P. 5 mg)\n <\/td>\n Thiamazole & other\n related substances\n <\/td><\/tr>
\n Secef – CV (Cefixime &\n Potassium Clavulanate Tablets)\n <\/td>\n Assay of Cefixime and\n Postassium Clavulanate\n <\/td><\/tr>
\n Misopres -200 (Misoprostol\n Tablets I.P. 200 mcg)\n <\/td>\n Assay\n <\/td><\/tr>
\n Misoprostol Tablets I.P. 200\n mcg\n <\/td>\n Assay\n <\/td><\/tr>
\n LEVOCET Levocetirizine\n Tablets IP 5 mg\n <\/td>\n Description\n <\/td><\/tr>
\n BUDISON 0.5 Respules\n (Budenoside, Nebuliser Suspension BP (0.5 mg) \u2013 2 ml\n <\/td>\n Assay & Related\n Substances\n <\/td><\/tr>
\n Clopidogrel & Aspirin\n Tablets I.P.\n <\/td>\n Free Salicylic Acid (Related\n substances for Asprin)\n <\/td><\/tr>
\n RL 500ml (Compound Sodium\n Lactate Injection IP) (Ringer Lactate Solution for Injection)\n <\/td>\n Bacterial Endotoxins\n <\/td><\/tr>
\n Flavosil -200 (Flavoxate\n Hydrochloride Tablets IP 200 mg)\n <\/td>\n Assay\n <\/td><\/tr>
\n Vildazem M 1000 (Vildagliptin\n 50 mg & Metformin Hydrochloride 1000 mg Tablets I.P.)\n <\/td>\n Disintegration\n <\/td><\/tr>
\n Losacon-H (Losartan Potassium\n & Hydrochlorothiazide Tablets I.P.)\n <\/td>\n Assay of Hydrochlorthiazide\n <\/td><\/tr>
\n Alumina, Magnesia &\n Simethicone Tablets U.S.P.\n <\/td>\n Assay of Simethicone\n <\/td><\/tr>
\n Propoven Injection 50ml\n (Propofol Emulsion for Injection IP 10mg\/ml)\n <\/td>\n Free Fatty Acid and Assay\n <\/td><\/tr>
\n Propomit Injection 20 ml\n (Propofol Emulsion for Injection IP 10mg\/ml)\n <\/td>\n Free Fatty Acid\n <\/td><\/tr>
\n NEXOFOL\n Injection 20 ml (Propofol Emulsion for Injection IP 10mg\/ml)\n <\/td>\n Assay\n <\/td><\/tr>
\n Ciprofloxacin\n Tablets IP 500 mg\n <\/td>\n Test for Dissolution\n <\/td><\/tr>
\n Norfloxacin\n Tablets I.P. 400 mg\n <\/td>\n Dissolution Test\n <\/td><\/tr>
\n FEXOFENADINE\n HCL Tablets IP 120 mg (REFEXO Tablets 120 mg)\n <\/td>\n Dissolution\n <\/td><\/tr>
\n DIVALPROEX\n SODIUM Tablets IP 500 mg\n <\/td>\n Dissolution (Buffer Stage)\n <\/td><\/tr>
\n Prolongedrelease\n Sodium Valproate Tablet BP 500 mg\n <\/td>\n Description\n <\/td><\/tr>
\n Zinc\n Sulphate Dispersible Tablets IP\n <\/td>\n Disintegration test\n <\/td><\/tr>
\n THIOCOLCHICOSI\n DE CAPSULES IP 4 mg\n <\/td>\n Assay\n <\/td><\/tr>
\n POVIDONE\n Iodine Solution IP 10% W\/V\n <\/td>\n pH & Assay\n <\/td><\/tr>
\n Propofol\n Emulsion for Injection IP 10 mg\/ml (PROPOVEN INJECTION )\n <\/td>\n Description, pH, Free fatty\n acid, Propofol dimer, Bacterial Endotoxins Sterility\n <\/td><\/tr>
\n Propofol\n Injection IP 1%w\/v (NEOROF INJECTION )\n <\/td>\n pH\n <\/td><\/tr><\/tbody><\/table>\n\n\n\n

Conclusion<\/h2>\n\n\n\n

The CDSCO comes with a list of Drugs, Medical Devices<\/strong><\/a>, and Cosmetics which are not of standard quality or spurious or misbranded every month. In September 2020, the CDSCO declared that it had tested 1456, of which 59 were not of standard quality and 1397 as of standard quality.<\/p>\n\n\n\n

Read our Article<\/b>:CDSCO Medical Device Registration for Paediatrics and Neonatology\n<\/a><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"

The CDSCO has noted that Spurious or Quality or Adulterated or Misbranded of Drugs products, medical devices and Cosmetic products are formulations manufactured concealing the true identity of the product and made to resemble another such product, especially any popular brand, to deceive the customer and cash in on the popularity of the original. The […]<\/p>\n","protected":false},"author":35,"featured_media":50329,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[2358],"tags":[2804],"acf":{"service_id":"508"},"authorName":"Karan Singh","authorImageUrl":"https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2022\/01\/processed-1-150x150.jpeg","authorDescription":"A legal writing enthusiast, a wanderer, and a zealous reader. After gaining a lot of knowledge about the diverse legal topics and developing research skills, Karan joined the league of legal content writers to deliver quality-rich blogs.","postViews":3663,"readingTime":3,"_links":{"self":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/50314"}],"collection":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/comments?post=50314"}],"version-history":[{"count":16,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/50314\/revisions"}],"predecessor-version":[{"id":50331,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/50314\/revisions\/50331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media\/50329"}],"wp:attachment":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media?parent=50314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/categories?post=50314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/tags?post=50314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}